. 2018 Mar; 97(6):622-626.
doi: 10.1177/0022034518759464.

Tumor Immunology and Immunotherapy for Head and Neck Squamous Cell Carcinoma

J M Moskovitz 1 R L Ferris 2 
  • PMID: 29489423
  •     46 References
  •     10 citations


The immune system plays an important role in the evolution of malignancy and has become an important target for novel antineoplastic agents. This review article focuses on key features of tumor immunology, including the role of immunotherapy in general and as it pertains to head and neck squamous cell carcinoma. Side effects, resistance mechanisms, and therapeutic monitoring strategies pertaining to immunotherapy are discussed.

Keywords: T lymphocyte; cancer biology; checkpoint receptors; clinical trials; immune resistance; neoadjuvant immunotherapy.

Cancer immunoediting: from immunosurveillance to tumor escape.
Gavin P Dunn, Allen T Bruce, +2 authors, Robert D Schreiber.
Nat Immunol, 2002 Oct 31; 3(11). PMID: 12407406
Highly Cited. Review.
Dynamics of cell surface molecules during T cell recognition.
Mark M Davis, Michelle Krogsgaard, +5 authors, Lauren Ehrlich.
Annu Rev Biochem, 2003 Oct 07; 72. PMID: 14527326
Peptide-based vaccines for cancer immunotherapy.
Joeli A Brinkman, Steven C Fausch, Jeffrey S Weber, W Martin Kast.
Expert Opin Biol Ther, 2004 Mar 05; 4(2). PMID: 14998777
Memory CD8 T-cell differentiation during viral infection.
E John Wherry, Rafi Ahmed.
J Virol, 2004 May 14; 78(11). PMID: 15140950    Free PMC article.
Highly Cited. Review.
Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck.
Iris Kuss, Bridget Hathaway, +2 authors, Theresa L Whiteside.
Clin Cancer Res, 2004 Jun 03; 10(11). PMID: 15173082
Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223).
Creg J Workman, Dario A A Vignali.
J Immunol, 2005 Jan 07; 174(2). PMID: 15634887
Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL.
Andrés López-Albaitero, Jayakar V Nayak, +5 authors, Robert L Ferris.
J Immunol, 2006 Mar 07; 176(6). PMID: 16517708
Molecular signature of CD8+ T cell exhaustion during chronic viral infection.
E John Wherry, Sang-Jun Ha, +7 authors, Rafi Ahmed.
Immunity, 2007 Oct 24; 27(4). PMID: 17950003
Highly Cited.
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
F Stephen Hodi, Marcus Butler, +17 authors, Glenn Dranoff.
Proc Natl Acad Sci U S A, 2008 Feb 22; 105(8). PMID: 18287062    Free PMC article.
Highly Cited.
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.
Shawn D Blackburn, Haina Shin, +7 authors, E John Wherry.
Nat Immunol, 2008 Dec 02; 10(1). PMID: 19043418    Free PMC article.
Highly Cited.
Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells.
Joseph F Grosso, Monica V Goldberg, +7 authors, Charles G Drake.
J Immunol, 2009 May 21; 182(11). PMID: 19454660    Free PMC article.
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.
Karl S Peggs, Sergio A Quezada, +2 authors, James P Allison.
J Exp Med, 2009 Jul 08; 206(8). PMID: 19581407    Free PMC article.
Highly Cited.
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.
Jedd D Wolchok, Axel Hoos, +9 authors, F Stephen Hodi.
Clin Cancer Res, 2009 Nov 26; 15(23). PMID: 19934295
Highly Cited.
PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice.
Taku Okazaki, Il-mi Okazaki, +9 authors, Tasuku Honjo.
J Exp Med, 2011 Feb 09; 208(2). PMID: 21300912    Free PMC article.
Vstm3 is a member of the CD28 family and an important modulator of T-cell function.
Steven D Levin, David W Taft, +21 authors, Katherine E Lewis.
Eur J Immunol, 2011 Mar 19; 41(4). PMID: 21416464    Free PMC article.
IL-18 induces PD-1-dependent immunosuppression in cancer.
Magali Terme, Evelyn Ullrich, +14 authors, Laurence Zitvogel.
Cancer Res, 2011 Jul 05; 71(16). PMID: 21724589
Highly Cited.
The blockade of immune checkpoints in cancer immunotherapy.
Drew M Pardoll.
Nat Rev Cancer, 2012 Mar 23; 12(4). PMID: 22437870    Free PMC article.
Highly Cited. Review.
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.
Janis M Taube, Robert A Anders, +8 authors, Lieping Chen.
Sci Transl Med, 2012 Mar 31; 4(127). PMID: 22461641    Free PMC article.
Highly Cited.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, +27 authors, Mario Sznol.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658127    Free PMC article.
Highly Cited.
Radiation, inflammation, and immune responses in cancer.
Gabriele Multhoff, Jürgen Radons.
Front Oncol, 2012 Jun 08; 2. PMID: 22675673    Free PMC article.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo.
Linda C Sandin, Fredrik Eriksson, +3 authors, Sara M Mangsbo.
Oncoimmunology, 2014 Apr 05; 3(1). PMID: 24701377    Free PMC article.
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.
Janis M Taube, Alison Klein, +7 authors, Robert A Anders.
Clin Cancer Res, 2014 Apr 10; 20(19). PMID: 24714771    Free PMC article.
Highly Cited.
Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses.
Nicole Joller, Ester Lozano, +13 authors, Vijay K Kuchroo.
Immunity, 2014 Apr 22; 40(4). PMID: 24745333    Free PMC article.
Highly Cited.
Opportunistic infections in patients treated with immunotherapy for cancer.
Chrisann Kyi, Matthew D Hellmann, +2 authors, Michael A Postow.
J Immunother Cancer, 2014 Jul 06; 2. PMID: 24991413    Free PMC article.
Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence.
Andreas R de Biasi, Jonathan Villena-Vargas, Prasad S Adusumilli.
Clin Cancer Res, 2014 Sep 11; 20(21). PMID: 25204552    Free PMC article.
Molecular and cellular insights into T cell exhaustion.
E John Wherry, Makoto Kurachi.
Nat Rev Immunol, 2015 Jul 25; 15(8). PMID: 26205583    Free PMC article.
Highly Cited. Review.
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, F Stephen Hodi, Jedd D Wolchok.
N Engl J Med, 2015 Sep 24; 373(13). PMID: 26398076
Highly Cited.
Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer.
Fernando Concha-Benavente, Raghvendra M Srivastava, +5 authors, Robert L Ferris.
Cancer Res, 2015 Dec 18; 76(5). PMID: 26676749    Free PMC article.
Highly Cited.
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.
S Champiat, O Lambotte, +20 authors, A Marabelle.
Ann Oncol, 2015 Dec 31; 27(4). PMID: 26715621
Highly Cited. Review.
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
F Stephen Hodi, Wen-Jen Hwu, +18 authors, Jedd D Wolchok.
J Clin Oncol, 2016 Mar 10; 34(13). PMID: 26951310    Free PMC article.
Highly Cited.
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.
Suzanne L Topalian, Janis M Taube, Robert A Anders, Drew M Pardoll.
Nat Rev Cancer, 2016 Apr 16; 16(5). PMID: 27079802    Free PMC article.
Highly Cited. Review.
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Tanguy Y Seiwert, Barbara Burtness, +9 authors, Laura Q Chow.
Lancet Oncol, 2016 Jun 02; 17(7). PMID: 27247226
Highly Cited.
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.
Jonathan M Pitt, Marie Vétizou, +8 authors, Laurence Zitvogel.
Immunity, 2016 Jun 23; 44(6). PMID: 27332730
Highly Cited. Review.
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
Laura Q M Chow, Robert Haddad, +19 authors, Tanguy Y Seiwert.
J Clin Oncol, 2016 Sep 21; 34(32). PMID: 27646946    Free PMC article.
Highly Cited.
Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix.
Damian T Rieke, Sebastian Ochsenreither, +4 authors, Ulrich Keilholz.
Oncotarget, 2016 Sep 30; 7(46). PMID: 27683114    Free PMC article.
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Robert L Ferris, George Blumenschein, +20 authors, Maura L Gillison.
N Engl J Med, 2016 Oct 11; 375(19). PMID: 27718784    Free PMC article.
Highly Cited.
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
Jake S O'Donnell, Mark J Smyth, Michele W L Teng.
Genome Med, 2016 Oct 27; 8(1). PMID: 27782862    Free PMC article.
Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.
Julie E Bauman, Ezra Cohen, +17 authors, Shakun Malik.
Cancer, 2016 Dec 03; 123(7). PMID: 27906454    Free PMC article.
Resistance to PD1/PDL1 checkpoint inhibition.
Jake S O'Donnell, Georgina V Long, +2 authors, Mark J Smyth.
Cancer Treat Rev, 2016 Dec 13; 52. PMID: 27951441
Highly Cited. Review.
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.
Joshua Bauml, Tanguy Y Seiwert, +15 authors, Robert Haddad.
J Clin Oncol, 2017 Mar 23; 35(14). PMID: 28328302    Free PMC article.
Highly Cited.
Immunotherapy in head and neck cancer: aiming at EXTREME precision.
Petr Szturz, Jan B Vermorken.
BMC Med, 2017 Jun 03; 15(1). PMID: 28571578    Free PMC article.
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Jedd D Wolchok, Vanna Chiarion-Sileni, +30 authors, James Larkin.
N Engl J Med, 2017 Sep 12; 377(14). PMID: 28889792    Free PMC article.
Highly Cited.
Tim-3, Lag-3, and TIGIT.
Nicole Joller, Vijay K Kuchroo.
Curr Top Microbiol Immunol, 2017 Sep 14; 410. PMID: 28900677    Free PMC article.
Quality-of-life outcomes in patients with advanced melanoma: A review of the literature.
Karen A Malkhasyan, Yousef Zakharia, Mohammed Milhem.
Pigment Cell Melanoma Res, 2017 Sep 28; 30(6). PMID: 28950054
Requirement of Treg-intrinsic CTLA4/PKCη signaling pathway for suppressing tumor immunity.
Christophe Pedros, Ann J Canonigo-Balancio, Kok-Fai Kong, Amnon Altman.
JCI Insight, 2017 Dec 08; 2(23). PMID: 29212947    Free PMC article.
Immunotherapeutics for head and neck squamous cell carcinoma stem cells.
X Qian, F Leonard, +5 authors, A E Albers.
HNO, 2020 Jan 31; 68(2). PMID: 31996933
Impact of Epigenetic Regulation on Head and Neck Squamous Cell Carcinoma.
M V Bais.
J Dent Res, 2019 Jan 08; 98(3). PMID: 30615537    Free PMC article.
Immunoregulatory Potential of Exosomes Derived from Cancer Stem Cells.
Shannon M Clayton, Joehleen A Archard, +8 authors, Johnathon D Anderson.
Stem Cells Dev, 2019 Dec 21; 29(6). PMID: 31856674    Free PMC article.
Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma.
Lili Ren, Matthias Leisegang, +10 authors, Yusuke Nakamura.
Oncoimmunology, 2019 Mar 25; 8(4). PMID: 30906664    Free PMC article.
Molecular biology of oral cavity squamous cell carcinoma.
Phillip J Hsu, Kenneth Yan, +2 authors, Nishant Agrawal.
Oral Oncol, 2020 Jan 10; 102. PMID: 31918173    Free PMC article.
Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding.
Lawrence P Andrews, Ashwin Somasundaram, +14 authors, Dario A A Vignali.
Sci Immunol, 2020 Jul 19; 5(49). PMID: 32680952    Free PMC article.
Increased Tumor Immune Microenvironment CD3+ and CD20+ Lymphocytes Predict a Better Prognosis in Oral Tongue Squamous Cell Carcinoma.
Raísa Sales de Sá, Marisol Miranda Galvis, +8 authors, Luiz Paulo Kowalski.
Front Cell Dev Biol, 2021 Mar 16; 8. PMID: 33718347    Free PMC article.
Biomarkers for Immunotherapy of Oral Squamous Cell Carcinoma: Current Status and Challenges.
Alhadi Almangush, Ilmo Leivo, Antti A Mäkitie.
Front Oncol, 2021 Mar 26; 11. PMID: 33763354    Free PMC article.
Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma.
Teng Wei, Matthias Leisegang, +11 authors, Lili Ren.
Oncoimmunology, 2021 Jun 10; 10(1). PMID: 34104546    Free PMC article.
Preoperative Immunotherapy in the Multidisciplinary Management of Oral Cavity Cancer.
Ramez Philips, Chihun Han, +4 authors, Jennifer Johnson.
Front Oncol, 2021 Jul 20; 11. PMID: 34277428    Free PMC article.